<p>GSK plc has published the transcript of its Full Year 2025 results conference call, held on February 4, 2026. The event was attended by senior management, including Luke Miels, Nina Mojas, Deborah Waterhouse, Tony Wood, Julie Brown, and David Redfern, who participated in the Q&amp;A session. During the call, management highlighted GSK’s strong performance in 2025 and provided guidance for continued topline growth and operating leverage in 2026. Key topics included the company’s strategy to deliver its 2031 ambitions and address the upcoming loss of exclusivity for dolutegravir, as well as continued efforts to accelerate pipeline innovation and enhance product competitiveness. Management emphasized a shift towards a more product-centric approach and the need for increased scientific agility. “Products are the key in this business, and we need to be more product-centric,” stated a senior executive. Deborah Waterhouse, Head of the HIV division, provided an update on the pipeline, noting, “We’re on track to select our Q6M treatment regimen in the middle of the year,” and outlined the expected impact of exclusivity loss, with a dip anticipated in 2029 and 2030, followed by a return to growth in 2031 and beyond. “HIV will be a big contributor to GSK’s success this decade and into the future,” she added. The full transcript can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

LABD

SBIO

Reuters

Direxion S&P Biotech Bear 3X

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

SPDR S&P Biotech

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

GlaxoSmithKline plc

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

GSK plc Publishes Transcript of Full Year 2025 Results Conference Call and Webcast for Investors and Analysts